首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1542945

全球子宮內避孕器 (IUD) 市場 - 2024-2031

Global Intrauterine Contraceptive Devices (IUD) Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

2023年，全球子宮內避孕器（IUD）市場規模達31億美元，預計2031年將達到44.5億美元，2024-2031年預測期間複合年成長率為4.7%。

子宮內避孕器是一種用於節育的小型塑膠 T 形裝置。它被插入子宮並停留以防止懷孕。子宮內避孕器可防止精子使卵子受精，並防止受精卵植入子宮。子宮內避孕器在預防和治療子宮內膜癌和其他疾病的應用也正在研究中。

子宮內避孕器是當今最有效的避孕形式之一，其失敗率與各種形式的絕育手術相似。子宮內避孕器有許多好處，包括功效、易用性、可逆性和患者滿意度，特別是長期使用的時間和成本。本活動回顧了子宮內避孕器放置和取出的適應症、禁忌症、風險和益處。這項活動還將詳細介紹跨專業團隊在為接受子宮內避孕器放置和取出的患者提供最佳護理方面的作用。

市場動態：

司機

病毒感染流行率不斷上升

子宮內避孕器（IUD）市場的需求是由多種因素所驅動的。人們意識的提高推動了市場的成長。此外，技術進步和政府措施將推動子宮內避孕器（IUD）市場的需求。例如，據聯合國稱，截至 2022 年 2 月，全球有 1.61 億人使用子宮內避孕器 (IUD) 作為避孕形式，使其成為全球最常見的方法之一。根據疾病預防控制中心(CDC) 的數據，截至2023 年12 月，在美國，20.4% 有性經驗的女性曾經使用過子宮內避孕器。使用者中，有14% 使用過子宮內避孕器，高於2002 年為2.4%。 49 歲之間的女性使用子宮內避孕器的比例最低，為5-6%。

此外，根據 nih.gov 2023 年 7 月發布的一篇文章，子宮內避孕器避孕方法的使用差異很大。東亞、東南亞和北非為 18%，突尼斯為 27.8%，埃及為 36.1%。儘管現代避孕方法的使用率幾乎增加了兩倍； 2005 年至 2019 年間，衣索比亞已婚婦女的比例從 14% 增加到 41%，子宮內避孕器對避孕方法組合的貢獻可以忽略不計。子宮內避孕器的使用率從亞的斯亞貝巴的 5.2% 到甘貝拉地區的 0.4% 到衣索比亞索馬利亞地區的零。

限制

子宮內避孕器相關的高成本以及子宮內避孕器引起的副作用等因素預計將阻礙市場的發展。使用子宮內避孕器的女性可能會出現副作用，例如月經週期不規則、經期出血增加和經期痙攣惡化。在少數情況下，它可能會導致子宮外孕和骨盆疼痛。

細分市場分析

全球子宮內避孕器市場根據類型、最終用戶和地區進行細分。

銅子宮內避孕器佔據子宮內避孕器市佔率約45.8%

預計銅子宮內避孕器細分市場將在預測期內佔據最大的市場佔有率。在這一領域，政府監管的發展以及私營製造商用於研究工作的資金不斷增加將推動該市場的發展。

非激素銅子宮內避孕器是一種小型塑膠裝置，其框架上纏繞著銅線。它被插入子宮（子宮），子宮內避孕器不斷釋放少量的銅。含銅子宮內避孕器的避孕效果超過 99%，永續使用長達 5 - 10 年（取決於類型）。如果在 40 歲或以上時插入含銅子宮內避孕器，則可在停經前避孕。

例如，2023 年 10 月，Sebela Pharmaceuticals 旗下的 Sebela Women's Health Inc. 宣布了來自研究性銅 175 mm2 子宮內避孕器 (IUD) 的關鍵 3 期開放標籤研究的更多積極資料。最近三屆婦女健康科學大會上發表的資料為研究性下一代無激素子宮內避孕器提供了進一步的支持，如其關鍵的 3 期試驗所示。無激素銅 175 mm2 IUD 具有由鎳鈦諾製成的軟性框架，這種材料具有超彈性特性，可將銅策略性地放置在輸卵管口和子宮頸內口附近，以實現近端效果。

市場地域佔有率

北美約佔子宮內避孕器市場佔有率的48.6%

預計北美地區將在預測期內佔據最大的市場佔有率。該地區人們的意識不斷增強，有助於推動市場發展。

例如，2022 年8 月，美國食品藥物管理局(FDA) 批准了一份補充新藥申請，將Mirena（左炔諾孕酮子宮內緩釋系統）52 mg 子宮內避孕器(IUD) 延長一年，從而延長了使用子宮內避孕器(IUD) 的數量。此次批准是在一項 3 期試驗之後進行的，該試驗分析了 Mirena 對 362 名使用該產品超過 5 年的女性的有效性。使用6至8年，避孕效果超過99%，且未發現新的安全性發現。 Mirena 將荷爾蒙左旋諾孕酮釋放到子宮中以防止懷孕，並且可以治療採取子宮內避孕的女性 5 年的月經過多。

An intrauterine device is a small plastic T-shaped device used for birth control. It is inserted into the uterus where it stays to prevent pregnancy. Intrauterine devices prevent sperm from fertilizing an egg and prevent fertilized eggs from implanting in the uterus. The use of intrauterine devices is also being studied in the prevention and treatment of endometrial cancer and other conditions.

Intrauterine devices are one of the most effective forms of contraception available today, with rates of failure similar to various forms of sterilization. There are many benefits of IUDs, including efficacy, ease of use, reversible nature, and patient satisfaction, especially with time commitment for long-term use and cost. This activity reviews the indications, contraindications, risks, and benefits of intrauterine device placement and removal. This activity will also detail the role of the interprofessional team in providing patients who undergo intrauterine device placement and removal with the best possible care.

Market Dynamics: Drivers

Increasing prevalence of viral infections

The demand for the intrauterine contraceptive devices (IUD) market is driven by multiple factors. The increase in awareness among people propels the market growth. Furthermore, the demand for the intrauterine contraceptive devices (IUD) market will be fueled by technological advancements and government initiatives. For instance, according to the United Nations, as of February 2022, the United Nations reported that 161 million people worldwide use intrauterine devices (IUDs) as a form of contraception, making it one of the most common methods globally. In the United States, 20.4% of sexually experienced women have ever used an IUD, according to the CDC as of December 2023. In 2016, 14% of contraceptive users between the ages of 15 and 44 in the U.S. used an IUD, up from 2.4% in 2002. Women between the ages of 25 and 29 had the highest rates of IUD use at 19%, while those between 15 and 19 and 45 and 49 had the lowest rates at 5-6%.

Moreover, according to an article posted by nih.gov, in July 2023, the use of an IUD contraceptive method varies widely. 18% in Eastern and southeastern Asia, and Northern Africa, while it is 27.8% in Tunisia and 36.1% in Egypt. Even though the use of modern contraceptive methods has nearly tripled; increasing from 14% to 41% between 2005 and 2019 among married women in Ethiopia, the contribution of an IUD to the method mix is negligible. The utilization of an IUD varies from 5.2% in Addis Ababa to 0.4% in the Gambella region to null in the Somali region of Ethiopia.

Restraints

Factors such as high costs associated with IUDs and side effects caused due to IUDs are expected to hamper the market. Women who use IUDs may experience side effects such as irregular menstrual cycle, increased period bleeding, and worsening of period cramps. In a few cases, it may lead to ectopic pregnancies and pelvic pain.

Market Segment Analysis

The global intrauterine contraceptive devices market is segmented based on type, end-user, and region.

The segment copper IUD accounted for approximately 45.8% of the intrauterine contraceptive devices market share

The copper IUD segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research work would drive this market.

The non-hormonal copper IUD is a small plastic device with copper wire coiled (wrapped) around the frame. It is inserted into the uterus (womb) where the IUD constantly releases a small amount of copper. The copper IUDs are more than 99% effective at preventing pregnancy and can last for up to 5 - 10 years (depending on the type). A copper IUD can be used for contraception until menopause if inserted when one is 40 years of age or older.

For instance, in October 2023, Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced additional positive data from the pivotal Phase 3 open-label study of the investigational Copper 175 mm2 intra-uterine device (IUD). The data presented at three recent women's health scientific congresses provide further support for the investigational, next-generation, hormone-free IUD as exhibited in its pivotal phase 3 trial. The hormone-free Copper 175 mm2 IUD has a flexible frame made of nitinol, a material that has superelastic properties and allows for the copper to be strategically placed near the Ostia of the fallopian tubes and the internal os of the cervix for proximal effect.

Market Geographical Share

North America accounted for approximately 48.6% of the intrauterine contraceptive devices market share

North America region is expected to hold the largest market share over the forecast period. The growing awareness among people, in this region, helps to propel the market.

For instance, in August 2022, the US Food and Drug Administration (FDA) approved a supplemental New Drug Application for an extension of Mirena (levonorgestrel-releasing intrauterine system) 52 mg Intrauterine Device (IUD) for an additional year, extending the number of years it can be used to prevent pregnancy to 8 years. The approval follows a phase 3 trial which analyzed the effectiveness of Mirena in 362 women who have used the product for over 5 years. Contraceptive efficacy was over 99% from 6 to 8 years of use, and no new safety findings were found. Mirena releases the hormone levonorgestrel into the uterus to prevent pregnancy and can treat heavy periods for 5 years in women who take intrauterine contraception.

Market Segmentation

By Type

Hormonal IUD
Copper IUD

By End-User

Hospitals
Gynaecology Clinics
Community Healthcare Centers
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the global intrauterine contraceptive devices (IUD) market include Teva Pharmaceuticals, Bayer, Pregna, OCON Medical, Eurogine, SMB Corporation, Actavis, Agile, Besins Healthcare, and Pfizer among others.

Key Developments

In July 2024, 3Daughters, a clinical development company dedicated to advancing women's healthcare, announced the successful completion of an oversubscribed seed financing round, raising $4.7 million. This round saw participation from existing investors including Thairm Bio, Argosy Foundation, Wexford Science and Technology, UMass Amherst, and new undisclosed investors.
In November 2023, Bayer and CrossBay Medical announced a development and licensing agreement to create a single-handed inserter for intrauterine systems (IUS), integrating CrossBay's CrossGlide technology with Bayer's hormonal IUD portfolio. The new inserter, using CrossGlide technology, aims to potentially improve the comfort of intrauterine placement, and might reduce discomfort during the insertion process. This could also shorten the procedure time required by healthcare professionals.

Why Purchase the Report?

To visualize the global intrauterine contraceptive devices market segmentation based on type, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global intrauterine contraceptive devices market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global intrauterine contraceptive devices market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by End-User
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Awareness Among People
  - 4.1.1.2. Technological Advancements
  - 4.1.1.3. Government Initiatives

5. Restraints

5.1. High Costs Associated
5.2. Side Effects Caused due to IUDs

6. Opportunity

7. Impact Analysis

8. Industry Analysis

8.1. Porter's Five Force Analysis
8.2. Supply Chain Analysis
8.3. Pricing Analysis
8.4. Regulatory Analysis
8.5. Unmet Needs
8.6. PESTEL Analysis
8.7. Patent Analysis
8.8. SWOT Analysis

9. By Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.1.2. Market Attractiveness Index, By Drug Type
9.2. Hormonal IUD*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Copper IUD

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Homecare
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.5.1. The U.S.
  - 11.2.5.2. Canada
  - 11.2.5.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.5.1. Germany
  - 11.3.5.2. UK
  - 11.3.5.3. France
  - 11.3.5.4. Italy
  - 11.3.5.5. Spain
  - 11.3.5.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.5.1. Brazil
  - 11.4.5.2. Argentina
  - 11.4.5.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.5.1. China
  - 11.5.5.2. India
  - 11.5.5.3. Japan
  - 11.5.5.4. South Korea
  - 11.5.5.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Teva Pharmaceuticals*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Bayer
13.3. Pregna
13.4. OCON Medical
13.5. Eurogine
13.6. SMB Corporation
13.7. Actavis
13.8. Agile
13.9. Besins Healthcare
13.10. Pfizer (*LIST NOT EXHAUSTIVE)